Apax Partners leads spin-out of biomarker discovery company Sense Proteomic

Apax Partners leads spin-out of biomarker discovery company Sense Proteomic 

Sense Proteomic spun out of Procognia Ltd by Apax and its management team 

Maidenhead, UK: June 4, 2008, Sense Proteomic Ltd. today announced its spin out and its creation as a biomarker discovery company. It will now be focussing on using its proprietary protein array platform to discover novel panels of auto-antibody biomarkers in cancer and autoimmune diseases. Sense Proteomic was previously a subsidiary of the biosciences tools business Procognia Ltd, whose other subsidiary was listed on the Tel-Aviv stock exchange in 2007. 

Commenting on the deal, Amos Goren, of Apax, said, "Apax is pleased to be supporting the new management team of Sense Proteomic as they develop this exciting business. It is our belief that over the next few years growth in the diagnostic industry will revolutionise healthcare by enabling earlier and more targeted treatment of disease." 

Rachel Fallon Joint CEO said, "Apax's support will allow us to accelerate our biomarker programmes to validate the strong data we already have in both autoimmune diseases and cancer. This will allow us to maintain our position as leaders in the field." 

Chris Lyddon, Sense Proteomic's other Joint CEO, added "I am delighted that Apax has invested in Sense Proteomic, their support endorses both our technical approach and our business model". 

About Sense Proteomic Limited Sense Proteomic Limited is a biomarker discovery company utilising its proprietary protein array technology to discover and commercialise auto antibody biomarkers for cancer and autoimmune diseases. 

About Apax Partners Apax Partners is one of the world's leading private equity investment groups, operating across Europe, Israel, the United States and Asia. With over 30 years of direct investing experience, Apax Partners' Funds provide long-term equity financing to entrepreneurs to build and strengthen world-class companies. 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.